Magnesium Sulphate Neuroprotective Strategies for Preterm Deliveries
Status:
Not yet recruiting
Trial end date:
2024-07-15
Target enrollment:
Participant gender:
Summary
A Cochrane systematic review has confirmed that fetal exposure to magnesium sulphate given
before preterm birth has a neuroprotective role. This review also showed a significant
reduction in the rate of gross motor dysfunction in early childhood. Early Preterm birth (<
34+0 weeks) and very low birthweight (< 1,500 g) are the principal risk factors for cerebral
palsy. Multiple pregnancy accounts for over 10% of preterm births and has a higher incidence
of cerebral palsy than singleton pregnancy (twins have 7 times and triplets 47 times the risk
of cerebral palsy compared with singletons).